Antithrombotic & Anticoagulant Drugs Industry in 2012-2022 Reviewed by Visiongain

09 Mar 2012 • by Natalie Aster

With its R&D pipelines, the pharma industry has potential for improved treatments and increased revenues from blood-thinning agents. Many commercial opportunities remain.

Worldwide, numbers of heart attacks and strokes will rise this decade. Blood thinners will play important roles in medicine, helping to prevent and treat cardiovascular disorders.

New report “Antithrombotic/Anticoagulant Drugs: World Market 2012-2022” by Visiongain shows you potential revenues to 2022, with data, forecasts and iscussions.

This study assesses drugs to treat abnormal blood clotting in human beings. Discover sales predictions at world market, therapeutic class, product and national levels to 2022.

The report gives business research and analysis with many sales predictions. See the future of the industry and market.

Potential sales trends from 2012 are revealed for:

  • Platelet aggregation inhibitors 
  • Heparins 
  • Fibrinolytics 
  • Vitamin K antagonists 
  • Direct thrombin inhibitors 
  • Direct factor Xa inhibitors.

This report discusses activities of Eli Lilly, Boehringer Ingelheim, AstraZeneca, J&J, Bayer, Sanofi, Merck, Eisai, Daiichi Sankyo and other pharmaceutical companies.

Report Details:

Antithrombotic/Anticoagulant Drugs: World Market 2012-2022
Published: January, 2012
Pages: 120
Price: US$ 2.642,00

Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations.

More information can be found in the report “Antithrombotic/Anticoagulant Drugs: World Market 2012-2022” by Visiongain.

To order the report or ask for sample pages contact ps@marketpublishers.com

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com